Upstream Bio (UPB) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
9 Jun, 2026Opening remarks and agenda
Meeting called to order by the CEO, with board members, management, and independent auditor present.
Meeting conducted virtually in accordance with bylaws and Delaware law.
Rules of conduct and voting eligibility outlined; only stockholders of record as of April 13, 2026, or their proxies, may participate.
Board and executive committee updates
Two nominees, Edd Fleming and Liam Ratcliffe, were nominated for Class II director positions for three-year terms.
No stockholder nominations for directors were received in advance.
Shareholder proposals
Election of two Class II directors and ratification of PricewaterhouseCoopers LLP as independent auditor for fiscal year ending December 31, 2026, were the main proposals.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Upstream Bio
- Verekitug demonstrated robust efficacy and safety, advancing to Phase 3 for severe asthma and CRSWNP.UPB
Corporate presentation - Q2 net loss was $39.7M as Phase 3 trials advance and cash runway extends through 2027.UPB
Q2 2026 - Quarterly dosing with verekitug shows best-in-class efficacy in asthma and CRSwNP, phase III next year.UPB
Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Verekitug demonstrated robust efficacy and safety, advancing to Phase 3 for major respiratory diseases.UPB
Corporate presentation - Phase 3 trials in severe asthma and CRSwNP set for Q1 2027, with cash runway through 2027.UPB
Q1 2026 - Vote on two director elections and auditor ratification at the June 2026 virtual meeting.UPB
Proxy filing - Virtual meeting to elect directors, ratify auditor, and reinforce governance and oversight.UPB
Proxy filing - Verekitug demonstrated strong efficacy and safety in Phase 2, with Phase 3 trials set for 2027.UPB
Corporate presentation - Verekitug cut severe asthma exacerbations by 56% with durable efficacy and strong safety.UPB
Study result